Skip to main content

Richmond Timothy J.'s Form 4 filing

AbbVie Inc. (ABBV) · filed Dec 8, 2021

Accession no.
0001179110-21-010695
Filed
Dec 8, 2021
Trade date
Dec 6, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $6.04M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Richmond Timothy J.CIK 0001563523Officer (EVP, Chief HR Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 6, 2021Common Stock, $0.01 par valueMOption exerciseAcquired+50,350$58.88+$2,964,60850,350Direct
Dec 6, 2021Common Stock, $0.01 par valueSSaleDisposed−50,350$120.00−$6,042,0000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 6, 2021Common stockMOption exerciseDisposed−50,350$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1(c).

Read the full filing on SEC EDGAR (opens in a new tab)